Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...
The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...
Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
Zacks Investment Research on MSN6d
How to Play SRPT Stock After Patient Death Post DMD Therapy InfusionShares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback